| Congresso Brasileiro de Microbiologia 2023 | Resumo: 1143-2 | ||||
Resumo:The limited availability of effective treatment strategies for pathogenic microorganisms with multidrug resistance has increased the global burden of infectious diseases, leading to higher mortality rates, treatment duration, and costs. Therefore, the research and bioprospecting of new biocompounds of microbial origin is of great interest. Genomic analyses are a promising approach for the search for new compounds, since these biocompounds are synthesized by Biosynthetic Gene Clusters (BGCs), that act in the secondary metabolism of microorganisms and are often not expressed under normal laboratory cultivation conditions. Notably, actinobacteria are known to produce a large number of secondary metabolites, including antibiotics. In fact, more than 70% of the secondary metabolites of bacteria belonging to the actinobacteria group exhibit antimicrobial activities, and 64% of the known antibiotic classes of bacterial natural products are produced by these microorganisms. The potential for biologically active secondary metabolites from endophytic actinobacteria is considered to be as great as the potential achieved from actinobacteria from any other ecosystem. The CMRP NAPI/Taxonline collection has a large number of microbial isolates, however, the number of isolates belonging to the actinobacteria group is still under-represented and under-explored. In this context, this work aims to research and analyze the BGCs present in the the genomes of two actinobacteria belonging to the Streptomyces albidoflavus group (CMRP 4852 and CMRP 4854), in order to provide important new information to expand the knowledge about the biotechnological potential of the CMRP collection in several fronts. The genome sequencing was performed on the NEXTSEQ 1000/2000 platform using the Illumina DNA flex library, and low quality reads (Q<25) were removed before assembly. De novo genome assemblies were generated with SPAdes, and evaluated with QUAST and BUSCO. Genome annotations were performed with RAST and PROKKA, and BGCs were assessed with a pipeline combining AntiSMASH and HMMER, using hmm templates present in the PFAM database. For further evaluation, compounds and clusters present in the MIBiG platform will be used as reference for comparison and identification of the clusters present in both actinobacterial genomes. The genomes of isolates CMRP 4852 and CMRP 4854 displayed 73 and 119 contigs, with N50 values of 187,668 and 122,000 and L50 values of 11 and 18, respectively. Both genomes showed approximately 73.5% G+C, consistent with the higher GC content that is usually observed for actinobacteria, and the completeness levels for both genomes were approximately 99.7%. In terms of BGC content, isolates CMRP 4852 and CMRP 4854 presented, respectively, 35,3% and 23,3% of PKS, 17,6% and 11,7% of NRPS, 14,7% and 17,6% of Hybrids (PKS + NRPS), 11,7% and 8,8% of Terpenes, 11,7% and 14,7% of RiPPs, and other 8,8% unknown BGCs for both genomes. Overall, these results so far highlight the potential of the actinobacteria from CMRP collection as promising sources of novel and bioactive compounds, which can be further characterized and explored through in vitro approaches. Palavras-chave: Biocompounds, NEXTSEQ, Streptomyces Agência de fomento:CAPES, CNPQ | |||||